Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)
Hong Kong
· Delayed Price · Currency is HKD 24.35
-0.15 (-0.61%)
Apr 24, 2025, 4:08 PM HKT
HKG:6826 Revenue
In the year 2024, Shanghai Haohai Biological Technology had annual revenue of 2.70B CNY with 1.64% growth. Shanghai Haohai Biological Technology had revenue of 622.85M in the quarter ending December 31, 2024, a decrease of -7.35%.
Revenue
2.70B CNY
Revenue Growth
+1.64%
P/S Ratio
4.05
Revenue / Employee
1.25M CNY
Employees
2,158
Market Cap
11.62B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.70B | 43.62M | 1.64% |
| Dec 31, 2023 | 2.65B | 523.76M | 24.59% |
| Dec 31, 2022 | 2.13B | 380.16M | 21.72% |
| Dec 31, 2021 | 1.75B | 425.69M | 32.14% |
| Dec 31, 2020 | 1.32B | -271.07M | -16.99% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeiGene | 29.60B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| JD Health International | 61.89B |
| WuXi Biologics | 19.87B |
| Innovent Biologics | 10.03B |
| Akeso | 2.26B |
| Alibaba Health Information Technology | 31.39B |
| CSPC Pharmaceutical Group | 30.87B |